Abstract
Gram negative sepsis remains a high cause of mortality and places a great burden on public health finance in both the developed and developing world. Treatment of sepsis, using antibiotics, is often ineffective since pathology associated with the disease occurs due to dysregulation of the immune system (failure to return to steady state conditions) which continues after the bacteria, which induced the immune response, have been cleared. Immune modulation is therefore a rational approach to the treatment of sepsis but to date no drug has been developed which is highly effective, cheap and completely safe to use. One potential therapeutic agent is VIP, which is a natural peptide and is highly homologous in all vertebrates. In this review we will discuss the effect of VIP on components of the immune system, relevant to gram negative sepsis, and present data from animal models. Furthermore we will hypothesise on how these studies could be improved in future and speculate on the possible different ways in which VIP could be used in clinical medicine.
Keywords: Cytokine, inflammation, Sepsis, transcription bacteria, VIP, Systemic inflammatory response syndrome (SIRS), pathogen-associated molecular patterns (PAMPs), Toll-like receptor (TLR), cardiovascular collapse, dysregulated cytokine production, Pathogen Recognition, Therapeutic targets.
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:VIP as a Potential Therapeutic Agent in Gram Negative Sepsis
Volume: 12 Issue: 4
Author(s): Hiba Ibrahim, Paul Barrow and Neil Foster
Affiliation:
Keywords: Cytokine, inflammation, Sepsis, transcription bacteria, VIP, Systemic inflammatory response syndrome (SIRS), pathogen-associated molecular patterns (PAMPs), Toll-like receptor (TLR), cardiovascular collapse, dysregulated cytokine production, Pathogen Recognition, Therapeutic targets.
Abstract: Gram negative sepsis remains a high cause of mortality and places a great burden on public health finance in both the developed and developing world. Treatment of sepsis, using antibiotics, is often ineffective since pathology associated with the disease occurs due to dysregulation of the immune system (failure to return to steady state conditions) which continues after the bacteria, which induced the immune response, have been cleared. Immune modulation is therefore a rational approach to the treatment of sepsis but to date no drug has been developed which is highly effective, cheap and completely safe to use. One potential therapeutic agent is VIP, which is a natural peptide and is highly homologous in all vertebrates. In this review we will discuss the effect of VIP on components of the immune system, relevant to gram negative sepsis, and present data from animal models. Furthermore we will hypothesise on how these studies could be improved in future and speculate on the possible different ways in which VIP could be used in clinical medicine.
Export Options
About this article
Cite this article as:
Ibrahim Hiba, Barrow Paul and Foster Neil, VIP as a Potential Therapeutic Agent in Gram Negative Sepsis, Endocrine, Metabolic & Immune Disorders - Drug Targets 2012; 12 (4) . https://dx.doi.org/10.2174/187153012803832611
DOI https://dx.doi.org/10.2174/187153012803832611 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Calcineurin Inhibition and Development: Insights from Research Models
Current Enzyme Inhibition Pharmacological Treatments for Obesity
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Overview of Angiogenesis and the use of Bevacizumab in Patients with Malignant Gliomas
Current Signal Transduction Therapy Editorial: Limited Utility of the Handgrip Test for the Diagnosis of Diabetic Cardiovascular Autonomic Neuropathy: “There’s Time Enough, But None to Spare”
Current Vascular Pharmacology Mechanisms and Medical Management of Exercise Intolerance in Hypertrophic Cardiomyopathy
Current Pharmaceutical Design Torasemide in Hypertension and Heart Failure: Re-inventing Loop Diuretic Therapy?
Current Pharmaceutical Design Contractile Mechanisms in Diabetes-Related Erectile Dysfunction
Current Pharmaceutical Design Beneficial Effects of Traditional Chinese Medicine on the Treatment of Osteoporosis on Ovariectomised Rat Models
Current Drug Targets Arterial Stiffness and Hypertension: A Review of Mechanism and Clinical Relevance
Current Hypertension Reviews Assessing Medication Problems in those ≥ 65 Using the STOPP and START Criteria
Current Aging Science Clinical Pharmacology of Novel Selective COX-2 Inhibitors
Current Pharmaceutical Design Mechanism and Anticancer Activity of the Metabolites of an Endophytic Fungi from Eucommia ulmoides Oliv
Anti-Cancer Agents in Medicinal Chemistry Endothelial Function in Renal Transplant Recipients is Associated with Circulating Nitric Oxide, ACE Inhibitor Use and Time After Transplantation
Vascular Disease Prevention (Discontinued) Editorial [Hot Topic: Oxidative Stress Induced-Metabolic Imbalance, Mitochondrial Failure, And Cellular Hypoperfusion As Primary Pathogenetic Factors For The Development Of Alzheimer Disease Which Can Be Used As An Alternate And Successful Drug Treatment Strategy: Past, Present And Future (Guest Editor: Gjumrakch Aliev)]
CNS & Neurological Disorders - Drug Targets Editorial (Thematic Issue: Switching to Biological Agents in Autoimmune and Autoinflammatory Disorders: Current Targets and Therapy)
Current Medicinal Chemistry Recent Advances in GNAS Epigenetic Research of Pseudohypoparathyroidism
Current Molecular Medicine Cardiovascular Drug Development Using Radiopharmaceuticals
Current Pharmaceutical Design Effect of Oral Alkali Supplementation on Progression of Chronic Kidney Disease
Current Hypertension Reviews Role of Physician Gender in the Quality of Care of Cardiometabolic Diseases
Current Pharmaceutical Design New Insight Into A1 Adenosine Receptors in Diabetes Treatment
Current Pharmaceutical Design